Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex in Subjects With Ataxia Telangiectasia (NEAT)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary)
Indications Ataxia telangiectasia
Focus Registrational; Therapeutic Use
Acronyms the NEAT Trial
Sponsors EryDel

Most Recent Events

15 Dec 2025 According to a Quince Therapeutics media release, status changed from active, no longer recruiting to completed.
15 Dec 2025 According to a Quince Therapeutics media release, the last patient has completed their last visit in this trial. Topline results from this study are expected in the middle of Q1 2026.
10 Dec 2025 Results presented in a Quince Therapeutics media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com